# A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

> **NCT07096024** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1772 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** palbociclib plus fulvestrant
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT07096024
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-21
- **Primary completion:** 2025-02-07
- **Final completion:** 2025-02-07
- **Target enrollment:** 1772 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096024, "A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07096024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*